Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Excimer Femtosecond Ophthalmic Laser market

ID: MRFR/MED/35350-HCR
128 Pages
Nidhi Mandole
Last Updated: May 21, 2026

์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ ๋ ˆ์ด์ € ์‹œ์žฅ ์กฐ์‚ฌ ๋ณด๊ณ ์„œ๋Š” Apple๋ฆฌ์ผ€์ด์…˜๋ณ„(๊ตด์ ˆ ์ˆ˜์ˆ , ๋ฐฑ๋‚ด์žฅ ์ˆ˜์ˆ , ๊ฐ๋ง‰ ์ด์‹, ๋ง๋ง‰ ์ˆ˜์ˆ ), ์œ ํ˜•๋ณ„(์—‘์‹œ๋จธ ๋ ˆ์ด์ €, ํŽจํ† ์ดˆ ๋ ˆ์ด์ €), ์ตœ์ข… ์šฉ๋„๋ณ„(๋ณ‘์›, ์™ธ๋ž˜ ์ˆ˜์ˆ  ์„ผํ„ฐ, ์•ˆ๊ณผ ํด๋ฆฌ๋‹‰), ๊ธฐ์ˆ ๋ณ„(๋ ˆ์ด์ € ๋ณด์กฐ ๊ฐ๋ง‰ ๊ฐ๋ง‰์ฆ, ๊ด‘๊ตด์ ˆ ๊ฐ๋ง‰์ ˆ์ œ์ˆ , ๋ Œํ‹ฐํ˜ ์ถ”์ถœ) ๋ฐ ์ง€์—ญ๋ณ„(๋ถ๋ฏธ, ์œ ๋Ÿฝ, ๋‚จ๋ฏธ, ์•„์‹œ์•„ ํƒœํ‰์–‘, ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด) - ์„ฑ์žฅ ๋ฐ ์‚ฐ์—… ์˜ˆ์ธก 2025 To 2035

๊ณต์œ 
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Excimer Femtosecond Ophthalmic Laser market Infographic
์š”์•ฝ ๋ชฉ์ฐจ ์„ธ๋ถ„ํ™” PDF ๋‹ค์šด๋กœ๋“œ
  1. 1 ์„น์…˜ I: ์š”์•ฝ ๋ฐ ์ฃผ์š” ํ•˜์ด๋ผ์ดํŠธ
    1. 1.1 ์š”์•ฝ ์š”์•ฝ
      1. 1.1.1 ์‹œ์žฅ ๊ฐœ์š”
      2. 1.1.2 ์ฃผ์š” ๊ฒฐ๊ณผ
      3. 1.1.3 ์‹œ์žฅ ์„ธ๋ถ„ํ™”
      4. 1.1.4 ๊ฒฝ์Ÿ ํ™˜๊ฒฝ
      5. 1.1.5 ๋„์ „๊ณผ ๊ธฐํšŒ
      6. 1.1.6 ๋ฏธ๋ž˜ ์ „๋ง 2 ์„น์…˜ II: ๋ฒ”์œ„ ์ง€์ •, ๋ฐฉ๋ฒ•๋ก  ๋ฐ ์‹œ์žฅ ๊ตฌ์กฐ
    2. 2.1 ์‹œ์žฅ ์†Œ๊ฐœ
      1. 2.1.1 ์ •์˜
      2. 2.1.2 ์—ฐ๊ตฌ ๋ฒ”์œ„
        1. 2.1.2.1 ์—ฐ๊ตฌ ๋ชฉํ‘œ
        2. 2.1.2.2 ๊ฐ€์ •
        3. 2.1.2.3 ์ œํ•œ ์‚ฌํ•ญ
    3. 2.2 ์—ฐ๊ตฌ ๋ฐฉ๋ฒ•๋ก 
      1. 2.2.1 ๊ฐœ์š”
      2. 2.2.2 ๋ฐ์ดํ„ฐ ๋งˆ์ด๋‹
      3. 2.2.3 2์ฐจ ์—ฐ๊ตฌ
      4. 2.2.4 1์ฐจ ์—ฐ๊ตฌ
        1. 2.2.4.1 1์ฐจ ์ธํ„ฐ๋ทฐ ๋ฐ ์ •๋ณด ์ˆ˜์ง‘ ํ”„๋กœ์„ธ์Šค
        2. 2.2.4.2 1์ฐจ ์‘๋‹ต์ž ๋ถ„์„
      5. 2.2.5 ์˜ˆ์ธก ๋ชจ๋ธ
      6. 2.2.6 ์‹œ์žฅ ๊ทœ๋ชจ ์ถ”์ •
        1. 2.2.6.1 ์ƒํ–ฅ์‹ ์ ‘๊ทผ๋ฒ•
        2. 2.2.6.2 ํ•˜ํ–ฅ์‹ ์ ‘๊ทผ๋ฒ•
      7. 2.2.7 ๋ฐ์ดํ„ฐ ์‚ผ๊ฐ์ธก๋Ÿ‰
      8. 2.2.8 ๊ฒ€์ฆ 3 ์„น์…˜ III: ์งˆ์  ๋ถ„์„
    4. 3.1 ์‹œ์žฅ ์—ญํ•™
      1. 3.1.1 ๊ฐœ์š”
      2. 3.1.2 ๋“œ๋ผ์ด๋ฒ„
      3. 3.1.3 ์ œํ•œ ์‚ฌํ•ญ
      4. 3.1.4 ๊ธฐํšŒ
    5. 3.2 ์‹œ์žฅ ์š”์ธ ๋ถ„์„
      1. 3.2.1 ๊ฐ€์น˜ ์‚ฌ์Šฌ ๋ถ„์„
      2. 3.2.2 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ถ„์„
        1. 3.2.2.1 ๊ณต๊ธ‰์ž์˜ ๊ต์„ญ๋ ฅ
        2. 3.2.2.2 ๊ตฌ๋งค์ž์˜ ๊ต์„ญ๋ ฅ
        3. 3.2.2.3 ์‹ ๊ทœ ์ง„์ž…์ž์˜ ์œ„ํ˜‘
        4. 3.2.2.4 ๋Œ€์ฒด
        5. 3.2.2.5 ๊ฒฝ์Ÿ ๊ฐ•๋„
      3. 3.2.3 COVID-19 ์˜ํ–ฅ ๋ถ„์„
        1. 3.2.3.1 ์‹œ์žฅ ์˜ํ–ฅ ๋ถ„์„
        2. 3.2.3.2 ์ง€์—ญ ์˜ํ–ฅ
        3. 3.2.3.3 ๊ธฐํšŒ ๋ฐ ์œ„ํ˜‘ ๋ถ„์„ 4 ์„น์…˜ IV: ์ •๋Ÿ‰ ๋ถ„์„
    6. 4.1 ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ ๋ ˆ์ด์ € ์‹œ์žฅ, Apple๋ฆฌ์ผ€์ด์…˜ ๋ณ„ (USD ๋ฐฑ๋งŒ)
      1. 4.1.1 ๊ตด์ ˆ ์ˆ˜์ˆ 
      2. 4.1.2 ๋ฐฑ๋‚ด์žฅ ์ˆ˜์ˆ 
      3. 4.1.3 ๊ฐ๋ง‰์ˆ˜์ˆ 
      4. 4.1.4 ๋ง๋ง‰์ˆ˜์ˆ 
    7. 4.2 ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ๋ ˆ์ด์ € ์‹œ์žฅ, ์ตœ์ข… ์šฉ๋„๋ณ„(USD๋ฐฑ๋งŒ)
      1. 4.2.1 ๋ณ‘์›
      2. 4.2.2 ์•ˆ๊ณผ ์ง„๋ฃŒ์†Œ
      3. 4.2.3 ์™ธ๋ž˜ ์ˆ˜์ˆ  ์„ผํ„ฐ
    8. 4.3 ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ ๋ ˆ์ด์ € ์‹œ์žฅ, Technology (USD ๋ฐฑ๋งŒ)
      1. 4.3.1 ์—‘์‹œ๋จธ ๋ ˆ์ด์ €
      2. 4.3.2 ํŽจํ† ์ดˆ ๋ ˆ์ด์ €
      3. 4.3.3 ๋ณตํ•ฉ ๋ ˆ์ด์ € ์‹œ์Šคํ…œ
    9. 4.4 ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ์šฉ ๋ ˆ์ด์ € ์‹œ์žฅ, ํ™˜์ž ์ธ๊ตฌ ํ†ต๊ณ„(USD๋ฐฑ๋งŒ)
      1. 4.4.1 ์—ฐ๋ น ๊ทธ๋ฃน
      2. 4.4.2 ์„ฑ๋ณ„
      3. 4.4.3 ๊ธฐ์กด ์กฐ๊ฑด
    10. 4.5 ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ ๋ ˆ์ด์ € ์‹œ์žฅ, ์‹œ์ˆ  ์œ ํ˜•๋ณ„(USD๋ฐฑ๋งŒ)
      1. 4.5.1 ๋ ˆ์ด์ € ๋ณด์กฐ ํ˜„์žฅ ๊ฐ๋ง‰์ ˆ์ œ์ˆ 
      2. 4.5.2 ๊ด‘๊ตด์ ˆ ๊ฐ๋ง‰์ ˆ์ œ์ˆ 
      3. 4.5.3 ๋ ˆ์ด์ € ๋ฐฑ๋‚ด์žฅ ์ˆ˜์ˆ 
    11. 4.6 ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ ๋ ˆ์ด์ € ์‹œ์žฅ, ์ง€์—ญ๋ณ„(USD ๋ฐฑ๋งŒ)
      1. 4.6.1 ๋ถ๋ฏธ
        1. 4.6.1.1 US
        2. 4.6.1.2 ์บ๋‚˜๋‹ค
      2. 4.6.2 ์œ ๋Ÿฝ
        1. 4.6.2.1 ๋…์ผ
        2. 4.6.2.2 UK
        3. 4.6.2.3 ํ”„๋ž‘์Šค
        4. 4.6.2.4 ๋Ÿฌ์‹œ์•„
        5. 4.6.2.5 ์ดํƒˆ๋ฆฌ์•„
        6. 4.6.2.6 ์ŠคํŽ˜์ธ
        7. 4.6.2.7 ์œ ๋Ÿฝ ๋‚˜๋จธ์ง€ ์ง€์—ญ
      3. 4.6.3 APAC
        1. 4.6.3.1 ์ค‘๊ตญ
        2. 4.6.3.2 ์ธ๋„
        3. 4.6.3.3 ์ผ๋ณธ
        4. 4.6.3.4 ํ•œ๊ตญ
        5. 4.6.3.5 ๋ง๋ ˆ์ด์‹œ์•„
        6. 4.6.3.6 ํƒœ๊ตญ
        7. 4.6.3.7 ์ธ๋„๋„ค์‹œ์•„
        8. 4.6.3.8 ๋‚˜๋จธ์ง€ APAC
      4. 4.6.4 ๋‚จ๋ฏธ
        1. 4.6.4.1 ๋ธŒ๋ผ์งˆ
        2. 4.6.4.2 ๋ฉ•์‹œ์ฝ”
        3. 4.6.4.3 ์•„๋ฅดํ—จํ‹ฐ๋‚˜
        4. 4.6.4.4 ๋‚จ์•„๋ฉ”๋ฆฌ์นด ๋‚˜๋จธ์ง€ ์ง€์—ญ
      5. 4.6.5 MEA
        1. 4.6.5.1 GCC ๊ตญ๊ฐ€
        2. 4.6.5.2 ๋‚จ์•„ํ”„๋ฆฌ์นด
        3. 4.6.5.3 MEA 5 ์„น์…˜ V์˜ ๋‚˜๋จธ์ง€ ๋ถ€๋ถ„: ๊ฒฝ์Ÿ ๋ถ„์„
    12. 5.1 ๊ฒฝ์Ÿ ํ™˜๊ฒฝ
      1. 5.1.1 ๊ฐœ์š”
      2. 5.1.2 ๊ฒฝ์Ÿ ๋ถ„์„
      3. 5.1.3 ์‹œ์žฅ ์ ์œ ์œจ ๋ถ„์„
      4. 5.1.4 ์ฃผ์š” ์„ฑ์žฅ ์ „๋žต ํ—ฌ์Šค์ผ€์–ด
      5. 5.1.5 ๊ฒฝ์Ÿ ๋ฒค์น˜๋งˆํ‚น
      6. 5.1.6 ์ฃผ์š” ํ”Œ๋ ˆ์ด์–ด ๊ฐœ๋ฐœ ์ˆ˜ ์กฐ๊ฑด the Healthcare
      7. 5.1.7 ์ฃผ์š” ๊ฐœ๋ฐœ ๋ฐ ์„ฑ์žฅ ์ „๋žต
        1. 5.1.7.1 ์‹ ์ œํ’ˆ ์ถœ์‹œ/์„œ๋น„์Šค ๋ฐฐํฌ
        2. 5.1.7.2 ์ธ์ˆ˜ํ•ฉ๋ณ‘
        3. 5.1.7.3 ํ•ฉ์ž‘ ํˆฌ์ž
      8. 5.1.8 ์ฃผ์š” ํ”Œ๋ ˆ์ด์–ด ์žฌ๋ฌด ๋งคํŠธ๋ฆญ์Šค
        1. 5.1.8.1 ํŒ๋งค ๋ฐ ์˜์—… ์ด์ต
        2. 5.1.8.2 ์ฃผ์š” ํ”Œ๋ ˆ์ด์–ด R&D ์ง€์ถœ. 2023
    13. 5.2 ํšŒ์‚ฌ ํ”„๋กœํ•„
      1. 5.2.1 Alcon (CH)
        1. 5.2.1.1 ์žฌ๋ฌด ๊ฐœ์š”
        2. 5.2.1.2 ์ œ๊ณต๋˜๋Š” ์ œํ’ˆ
        3. 5.2.1.3 ์ฃผ์š” ๊ฐœ๋ฐœ
        4. 5.2.1.4 SWOT ๋ถ„์„
        5. 5.2.1.5 ์ฃผ์š” ์ „๋žต
      2. 5.2.2 Johnson & Johnson (US)
        1. 5.2.2.1 ์žฌ๋ฌด ๊ฐœ์š”
        2. 5.2.2.2 ์ œ๊ณต๋˜๋Š” ์ œํ’ˆ
        3. 5.2.2.3 ์ฃผ์š” ๊ฐœ๋ฐœ
        4. 5.2.2.4 SWOT ๋ถ„์„
        5. 5.2.2.5 ์ฃผ์š” ์ „๋žต
      3. 5.2.3 Bausch + Lomb (US)
        1. 5.2.3.1 ์žฌ๋ฌด ๊ฐœ์š”
        2. 5.2.3.2 ์ œ๊ณต๋˜๋Š” ์ œํ’ˆ
        3. 5.2.3.3 ์ฃผ์š” ๊ฐœ๋ฐœ
        4. 5.2.3.4 SWOT ๋ถ„์„
        5. 5.2.3.5 ์ฃผ์š” ์ „๋žต
      4. 5.2.4 Carl Zeiss (DE)
        1. 5.2.4.1 ์žฌ๋ฌด ๊ฐœ์š”
        2. 5.2.4.2 ์ œ๊ณต ์ œํ’ˆ
        3. 5.2.4.3 ์ฃผ์š” ๊ฐœ๋ฐœ
        4. 5.2.4.4 SWOT ๋ถ„์„
        5. 5.2.4.5 ์ฃผ์š” ์ „๋žต
      5. 5.2.5 Nidek (JP)
        1. 5.2.5.1 ์žฌ๋ฌด ๊ฐœ์š”
        2. 5.2.5.2 ์ œ๊ณต๋˜๋Š” ์ œํ’ˆ
        3. 5.2.5.3 ์ฃผ์š” ๊ฐœ๋ฐœ
        4. 5.2.5.4 SWOT ๋ถ„์„
        5. 5.2.5.5 ์ฃผ์š” ์ „๋žต
      6. 5.2.6 Ziemer ์•ˆ๊ณผ ์‹œ์Šคํ…œ (CH)
        1. 5.2.6.1 ์žฌ๋ฌด ๊ฐœ์š”
        2. 5.2.6.2 ์ œ๊ณต๋˜๋Š” ์ œํ’ˆ
        3. 5.2.6.3 ์ฃผ์š” ๊ฐœ๋ฐœ
        4. 5.2.6.4 SWOT ๋ถ„์„
        5. 5.2.6.5 ์ฃผ์š” ์ „๋žต
      7. 5.2.7 ๋ฃจ๋ฉ”๋‹ˆ์Šค(IL)
        1. 5.2.7.1 ์žฌ๋ฌด ๊ฐœ์š”
        2. 5.2.7.2 ์ œ๊ณต๋˜๋Š” ์ œํ’ˆ
        3. 5.2.7.3 ์ฃผ์š” ๊ฐœ๋ฐœ
        4. 5.2.7.4 SWOT ๋ถ„์„
        5. 5.2.7.5 ์ฃผ์š” ์ „๋žต
      8. 5.2.8 Surgical Specialties Corporation (CA)
        1. 5.2.8.1 ์žฌ๋ฌด ๊ฐœ์š”
        2. 5.2.8.2 ์ œ๊ณต ์ œํ’ˆ
        3. 5.2.8.3 ์ฃผ์š” ๊ฐœ๋ฐœ
        4. 5.2.8.4 SWOT ๋ถ„์„
        5. 5.2.8.5 ์ฃผ์š” ์ „๋žต
    14. 5.3 ๋ถ€๋ก
      1. 5.3.1 ์ฐธ๊ณ  ์ž๋ฃŒ
      2. 5.3.2 ๊ด€๋ จ ๋ณด๊ณ ์„œ

์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ์šฉ ๋ ˆ์ด์ € ์‹œ์žฅ ์„ธ๋ถ„ํ™”

Apple๋ฆฌ์ผ€์ด์…˜๋ณ„ ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ์šฉ ๋ ˆ์ด์ € ์‹œ์žฅ(USD Million, 2025-2035)

  • ๊ตด์ ˆ์ˆ˜์ˆ 
  • ๋ฐฑ๋‚ด์žฅ ์ˆ˜์ˆ 
  • ๊ฐ๋ง‰์™ธ๊ณผ
  • ๋ง๋ง‰์™ธ๊ณผ

์ตœ์ข… ์šฉ๋„๋ณ„ ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ์šฉ ๋ ˆ์ด์ € ์‹œ์žฅ(USD๋ฐฑ๋งŒ, 2025-2035)

  • ๋ณ‘์›
  • ์•ˆ๊ณผ ์ง„๋ฃŒ์†Œ
  • ์™ธ๋ž˜ ์ˆ˜์ˆ  ์„ผํ„ฐ

๊ธฐ์ˆ ๋ณ„ ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ์šฉ ๋ ˆ์ด์ € ์‹œ์žฅ(USD Million, 2025-2035)

  • ์—‘์‹œ๋จธ ๋ ˆ์ด์ €
  • ํŽจํ† ์ดˆ ๋ ˆ์ด์ €
  • ๋ณตํ•ฉ ๋ ˆ์ด์ € ์‹œ์Šคํ…œ

ํ™˜์ž ์ธ๊ตฌ ํ†ต๊ณ„๋ณ„ ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ ๋ ˆ์ด์ € ์‹œ์žฅ(USD ๋ฐฑ๋งŒ, 2025-2035)

  • ์—ฐ๋ น์ธต
  • ์„ฑ๋ณ„
  • ๊ธฐ์กด ์กฐ๊ฑด

์‹œ์ˆ  ์œ ํ˜•๋ณ„ ์—‘์‹œ๋จธ ํŽจํ† ์ดˆ ์•ˆ๊ณผ์šฉ ๋ ˆ์ด์ € ์‹œ์žฅ(USD๋ฐฑ๋งŒ, 2025-2035)

  • ๋ ˆ์ด์ € ๋ณด์กฐ ํ˜„์žฅ ๊ฐ๋ง‰์ ˆ์‚ญ์ˆ 
  • ๊ด‘๊ตด์ ˆ ๊ฐ๋ง‰์ ˆ์ œ์ˆ 
  • ๋ ˆ์ด์ € ๋ฐฑ๋‚ด์žฅ ์ˆ˜์ˆ 

๊ด€๋ จ ๋ณด๊ณ ์„œ

์ด ์‹œ์žฅ์— ์‚ฌ์šฉ ๊ฐ€๋Šฅํ•œ ์ง€์—ญ ๋ณด๊ณ ์„œ๊ฐ€ ์—†์Šต๋‹ˆ๋‹ค.

์ด ์‹œ์žฅ์— ์‚ฌ์šฉ ๊ฐ€๋Šฅํ•œ ๊ตญ๊ฐ€๋ณ„ ๋ณด๊ณ ์„œ๊ฐ€ ์—†์Šต๋‹ˆ๋‹ค.

Customer Stories
Case Study Cover Image
์‚ฌ๋ก€ ์—ฐ๊ตฌ

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019โ€“2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization โœ“ โœ“ โœ“
Direct Access to Analyst โœ“ โœ“ โœ“
Deliverable Format โœ“ โœ“ โœ“
Platform Access โœ— โœ— โœ“
Discount on Next Purchase 10% 15% 15%
Printable Versions โœ— โœ— โœ“